Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous dendritic cell vaccine loaded with autologous tumor homogenate in glioblastoma
2020-003755-15Phase 2Active
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- May 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of autologous dendritic cell vaccine and temozolomide in glioblastoma (GBM), sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Progression-free survival at 3 months from leukapheresis. Started May 2021; status: active.
02
Drugs
autologous dendritic cell vaccinetemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2020-003755-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003755-15.